Digest Network Come funziona
Network
/
Società
A2
Non verificato

A2 Biotherapeutics, Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieOncologiaSalute

11 comunicati stampa

Guarda tutti i comunicati
21/05/2026
Scienza
Biotecnologia
Farmaceutica
Oncologia
Salute
Medicina - Varie
Eventi
Industria
A2 Biotherapeutics Presents Safety and Efficacy Data from the EVEREST-2 Clinical Study, Including Update on the First Complete Response to CAR T-Cell Therapy in a Patient with Non-Small Cell Lung Cancer
Fonte
A2 Biotherapeutics, Inc.
Emittente
Business Wire
1.00
0
22/04/2026
Eventi
Industria
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
A2 Biotherapeutics to Highlight Progress of CAR T-Cell Clinical Programs in Three Poster Presentations During the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting
Fonte
A2 Biotherapeutics, Inc.
Emittente
Business Wire
1.00
0
01/04/2026
Industria
Biotecnologia
Igiene alimentare
Salute
Farmaceutica
Oncologia
A2 Biotherapeutics Receives U.S. FDA Fast Track Designation for A2B543, a Logic-Gated CAR T-Cell Therapy Enhanced with a Membrane-Tethered IL-12 Booster
Fonte
A2 Biotherapeutics, Inc.
Emittente
Business Wire
1.00
0
26/02/2026
Industria
Scienza
Biotecnologia
Farmaceutica
Oncologia
Salute
Medicina - Varie
A2 Biotherapeutics Doses First Patient in EVEREST-2 Study with A2B543, a Logic-Gated CAR T Cell Therapy Enhanced with a Membrane-Tethered IL-12 Booster
Fonte
A2 Biotherapeutics, Inc.
Emittente
Business Wire
1.00
0
08/01/2026
Industria
Scienza
Igiene alimentare
Biotecnologia
Medicina - Varie
Sanità
Farmaceutica
Salute
Oncologia
A2 Biotherapeutics Announces FDA Clearance of IND for A2B543 for Treatment of Adults with Recurrent Unresectable, Locally Advanced, or Metastatic Solid Tumors that Express Mesothelin and Have Lost HLA-A*02 Expression
Fonte
A2 Biotherapeutics, Inc.
Emittente
Business Wire
1.00
0
03/10/2025
Scienza
Biotecnologia
Farmaceutica
Oncologia
Sanità
Salute
Medicina - Varie
Eventi
Industria
A2 Bio to Present Early Safety and Efficacy Data from EVEREST-2 Study during 2025 Annual Meeting of the Society for Immunotherapy of Cancer
Fonte
A2 Biotherapeutics, Inc.
Emittente
Business Wire
1.00
0
08/09/2025
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Eventi
Industria
A2 Biotherapeutics Presents Data from Ongoing Phase 1/2 EVEREST-2 Study During the International Association for the Study of Lung Cancer 2025 World Conference on Lung Cancer
Fonte
A2 Biotherapeutics, Inc.
Emittente
Business Wire
1.00
0
26/06/2025
Oncologia
Salute
Biologia
Biotecnologia
Medicina - Varie
Farmaceutica
Industria
A2 Bio Announces First Patient Dosed in DENALI-1 Phase 1/2 Clinical Study of A2B395, a Novel Allogeneic Precision CAR T Cell Therapy for Patients with Solid Tumors that Express EGFR
Fonte
A2 Biotherapeutics, Inc.
Emittente
Business Wire
1.00
0
09/01/2025
Industria
Oncologia
Salute
Biotecnologia
Medicina - Varie
Farmaceutica
A2 Biotherapeutics Closes $80 Million Series C Financing to Advance Clinical Development of Its Precision Cell Therapies Using Its Proprietary Tmod™ Technology Platform
Fonte
A2 Biotherapeutics, Inc.
Emittente
Business Wire
1.00
0
09/11/2024
Eventi
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
A2 Bio Highlights Progress of Tmod™ CAR T-Cell Clinical Programs During 2024 Annual Meeting of the Society for Immunotherapy of Cancer
Fonte
A2 Biotherapeutics, Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0